Novo Nordisk

Company Overview

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with operations in 168 countries and a global workforce of more than 48,000 employees. The company is a world leader in the treatment of diabetes, obesity, and related cardiometabolic conditions, as well as rare blood disorders and rare endocrine diseases. In 2025, Novo Nordisk reported revenues of approximately 309 billion Danish kroner (approximately $46.8 billion), an increase of around 11% versus 2024. The company is majority-controlled through voting shares by Novo Holdings, the investment arm of the Novo Nordisk Foundation.

Headquarters and Global Presence

Novo Nordisk is headquartered in Bagsværd, a suburb of Copenhagen, Denmark. The company markets its products in 168 countries and operates manufacturing facilities across Denmark, the United States, France, Brazil, and China, among others. Following its acquisition of Catalent manufacturing sites, Novo Nordisk has significantly expanded its global production capacity for injectable GLP-1 medicines, which had faced supply constraints during the rapid uptake of Ozempic and Wegovy. Research and development operations are based primarily in Denmark, the United States, and China.

Founding and History

Novo Nordisk was established in its current form in 1989 following the merger of Novo Industri and Nordisk Gentofte, though the predecessor companies trace their roots to 1923 when Scandinavian scientists first began producing insulin. The company played a pioneering role in insulin production, moving from animal-derived to recombinant human insulin in the 1980s. Novo Nordisk's modern era began with the development of GLP-1 receptor agonists: exenatide research paved the way for liraglutide (Victoza) and ultimately semaglutide (Ozempic and Wegovy), which transformed both diabetes care and created the modern obesity pharmacotherapy market.

Therapy Areas and Focus

Novo Nordisk's core commercial and research activities are concentrated in obesity and type 2 diabetes, where it holds a commanding global market position through the Ozempic (semaglutide injectable) and Wegovy (semaglutide injectable) franchises. In December 2025, the FDA approved oral Wegovy (once-daily semaglutide 25 mg), the first oral GLP-1 receptor agonist approved for weight management, with a full US launch in January 2026. In cardiovascular medicine, Rybelsus (oral semaglutide) received expanded FDA approval for cardiovascular risk reduction in October 2025. Novo Nordisk also has a significant rare disease presence, focused on haemophilia A and B (Esperoct, Refixia, NovoSeven) and rare endocrine conditions, and is developing treatments for metabolic-associated steatohepatitis (MASH).

Technology Platforms and Modalities

Novo Nordisk's core scientific capabilities lie in peptide engineering, protein design, and long-acting drug formulation. Its expertise in GLP-1 receptor agonism has been extended through combinations with amylin analogues, producing CagriSema (cagrilintide plus semaglutide), and through unimolecular dual agonism, exemplified by amycretin (combined GLP-1 and amylin receptor agonist). The company has also invested in small-molecule oral approaches to GLP-1 and related pathways through partnerships including the $2.2 billion collaboration with Septerna. In haematology, recombinant factor and bispecific antibody technologies are applied to haemophilia management. In MASH, the Akero Therapeutics acquisition adds the FGF21 analogue efruxifermin.

Key Pipeline and Programs

Novo Nordisk's pipeline is centred on next-generation obesity and cardiometabolic programmes. CagriSema, a fixed-dose once-weekly combination of cagrilintide (amylin analogue) and semaglutide, has met co-primary endpoints in late-stage studies and an NDA has been submitted to the FDA for obesity, with a regulatory decision expected in 2026. Amycretin, a unimolecular GLP-1 and amylin receptor agonist, outperformed Wegovy in Phase 1 and entered Phase 3 trials for weight management in Q1 2026. Oral Wegovy (semaglutide 25 mg) is approved in the US and under review by the EMA following submission in the second half of 2025. Efruxifermin (acquired with Akero Therapeutics) is in Phase 3 for MASH. The higher-dose subcutaneous Wegovy 7.2 mg is under FDA review following submission with a priority review voucher.

Key Personnel

Maziar Mike Doustdar became President and Chief Executive Officer of Novo Nordisk on 7 August 2025, the first non-Danish person to lead the company in its history. An Austrian–Iranian business executive born in 1970, Doustdar previously served as Novo Nordisk's Executive Vice President of International Operations, under which remit he more than doubled international sales to approximately DKK 112 billion. He succeeded Lars Fruergaard Jørgensen, who had led the company since 2017 and oversaw the transformation of Novo Nordisk into a global obesity medicine leader. The transition comes as the company navigates competitive pressures and the commercialisation of its next-generation portfolio.

Strategic Partnerships

Novo Nordisk has pursued a range of acquisitions and partnerships to sustain its leadership in obesity and expand into adjacent conditions. The acquisition of Akero Therapeutics added efruxifermin, a Phase 3 FGF21 analogue for MASH. A $2.2 billion collaboration with Septerna targets oral small-molecule GLP-1 and related receptor agonists for obesity, type 2 diabetes, and other cardiometabolic conditions. An in-licensing agreement with United Biotechnology (Hengqin) brings a dual glucagon/GLP-1 agonist (UBT-251) into the obesity pipeline. The Catalent manufacturing site acquisition has substantially increased Novo Nordisk's ability to supply injectable GLP-1 therapies to meet global demand. Through the Novo Nordisk Foundation, the company also invests extensively in basic research and global health access initiatives, including the delivery of semaglutide-based therapies in lower-income countries.

FAQ Section